HROW

Harrow Inc. (HROW) | Rumor.io

Harrow

HROW

Attention (50-day avg)0%

Attention rank (50-day avg)#905

Bullish sentiment (50-day avg)88%

Price to earnings ratio-225.7

Market capitalization1.2B

Earnings per share-0.99

Dividend yield (TTM)—

Revenue (annual)272.3M

Net income (annual)-5.1M

Social

What share of all stock conversation is about HROW?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0

Sep 11

*Harrow Health, Inc. ($HROW) has seen a significant drop in its stock price, down around 5% due to no company-specific news, with Opaleye reducing its position in Harrow by 15%.
The company's management has been criticized for not handling expectations well, and the loss of the chief accounting officer without a reasonable explanation has affected the stock price.
Despite the short-term struggles, the long-range outlook for Harrow is still positive, with a potential $1B run-rate revenue for 2027 and a strong product pipeline, including the ocular anesthetic IHEEZO, which is expected to become a leading product in the market.

Generated by AI

Sentiment

Of the messages about HROW that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	33.33% -3.51	74.84% -19.66	95.98% +5.29
Bearish	—	66.67% +3.51	25.16% +19.66	4.02% -5.29

Bullish· Aug 11

The company's products are gaining traction, with increasing screen time being a significant tailwind, and the product's performance is "fantastic" with predictable results.
The company's management is undeniably talented, and despite their perceived flaws, they have a textbook story of compound growth (40% CAGR) with potential for future growth.
The stock is undervalued, trading at 12x NTM EBITDA with EBITDA potentially growing at 50% CAGR for the next few years, and could double in value over the next 6 months if the company grows 30% QoQ and improves margins.

Bearish· May 12

The company's Q1 results were disappointing, with the business being very seasonal and Q1 being the weakest quarter, with various reasons including Vevye penetrating the DED market but ASP being down.
The management's guidance for 2026 expectations is uncertain, with Baum not convincingly articulating the mechanism, timing, or confidence on how they'd meet guidance, which is a big tell for a credibility discount.
The company's FY26 guidance was base case, but there is also a bear case, with expectations now at $340-355M and 2027 back to epic growth, indicating a potential decline in the stock price.

Generated by AI

Topics

Of the messages about HROW that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	52.31%	4.4%
Earnings	—	—	0%	5.76%
Technical Analysis	—	—	0%	2.46%
Macro	—	—	41.54%	43.78%
Analysts	—	—	6.15%	43.26%
Controversies	—	—	0%	0.34%

Earnings· Nov 10

Harrow Health, Inc. ($HROW) reported Q3 2025 revenue of $71.6 million, a 45% increase year-over-year, but missed consensus estimates.
The company's adjusted EBITDA was $22.7 million, and GAAP net income was $1.0 million, with a net income of $0.03 per share.
Harrow Health's earnings beat consensus estimates for adjusted EPS, but the revenue miss led to a 9% stock price drop.

Announcements· Sep 26

Harrow Health, Inc. ($HROW) has agreed to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company developing non-opioid sedation therapies for medical procedures.
The acquisition includes an initial cash payment of $4.3M, with contingent payments of up to $261M tied to milestones such as FDA approval and commercialization of Melt's sedation drug candidate.
Melt's sedation drug candidate, MELT-300, has the potential to become a blockbuster product, with annual revenue exceeding $1B, according to Harrow's CEO, Mark Baum.

Generated by AI

Community

Of the messages about HROW, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	87.5%	87.39%	57.54%
Newcomers	—	12.5%	12.61%	42.46%

Regulars· Sep 11

The regulars are focusing on the company's poor management of expectations, which has led to a loss of credibility and a negative impact on the stock price.
The IHEEZO product is seen as a key driver of growth, with a potential to become a game-changer in the ocular anesthesia market, and the company's recent clinical displacement study results are seen as a positive development.
The company's management is reaffirming its revenue goals for 2027, and is planning to introduce segment reporting across Ocular Surgery, Retina, and Ocular Surface, which is seen as a positive development for institutional analysts and investors.

Newcomers· Nov 11

The CEO's overpromising and missing revenue targets are major concerns, potentially leading to a decline in the company's stock price.
The company's profitability has seen significant growth, with adjusted EPS increasing by 37.5% and net income becoming profitable.
The stock price has been volatile, with a 16% drop after hours and a subsequent 8% gain, suggesting that market expectations and perceptions are in flux.

Generated by AI

News

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

Tipranks Press Release.

1mo agoThe Globe and Mail

Harrow Announces Second Quarter 2026 Financial Results

Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growthVEVYE secured an

1mo agofinance.yahoo.com

Also Discussed

Investors talking about HROW also mention

#	Name	Attention
1	Eton Pharmaceuticals, Inc.ETON	0%-0.01
2	NeurAxis, Inc.NRXS	0%0
3	PROCEPT BioRobotics Corp.PRCT	0%0
4	ClearPoint Neuro Inc.CLPT	0.03%+0.02
5	Pagaya Technologies Ltd. Class A Ordinary SharesPGY	0%+0
6	Inhibrx Biosciences, Inc.INBX	0%0
7	Bausch + Lomb CorporationBLCO	0%0
8	PolyPid Ltd.PYPD	0%new
9	Power Solutions International, Inc.PSIX	0%new
10	Aspen Aerogels IncASPN	0%0

Harrow Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S. market. Its portfolio includes prescription and non-prescription therapies used by eye care professionals to manage conditions affecting the front and back of the eye, such as dry eye disease, glaucoma, cataracts, retinal disorders, allergies, and infections. Harrow operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business, giving it a broad commercial footprint across eye care settings. The company’s products are used in physician offices, clinics, and surgical environments, supporting routine treatment as well as specialized ophthalmic care. Headquartered in Nashville, Tennessee, Harrow focuses on accessible eye care solutions and a product mix that spans branded, compounded, and other ophthalmic formulations.

Website

Location

1A Burton Hills Boulevard

Nashville, TN, 37215

United States

Social

What share of all stock conversation is about HROW?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0.01% +0

Sep 11

*Harrow Health, Inc. ($HROW) has seen a significant drop in its stock price, down around 5% due to no company-specific news, with Opaleye reducing its position in Harrow by 15%.
The company's management has been criticized for not handling expectations well, and the loss of the chief accounting officer without a reasonable explanation has affected the stock price.
Despite the short-term struggles, the long-range outlook for Harrow is still positive, with a potential $1B run-rate revenue for 2027 and a strong product pipeline, including the ocular anesthetic IHEEZO, which is expected to become a leading product in the market.

Generated by AI

Sentiment

Of the messages about HROW that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	33.33% -3.51	74.84% -19.66	95.98% +5.29
Bearish	—	66.67% +3.51	25.16% +19.66	4.02% -5.29

Bullish· Aug 11

The company's products are gaining traction, with increasing screen time being a significant tailwind, and the product's performance is "fantastic" with predictable results.
The company's management is undeniably talented, and despite their perceived flaws, they have a textbook story of compound growth (40% CAGR) with potential for future growth.
The stock is undervalued, trading at 12x NTM EBITDA with EBITDA potentially growing at 50% CAGR for the next few years, and could double in value over the next 6 months if the company grows 30% QoQ and improves margins.

Bearish· May 12

The company's Q1 results were disappointing, with the business being very seasonal and Q1 being the weakest quarter, with various reasons including Vevye penetrating the DED market but ASP being down.
The management's guidance for 2026 expectations is uncertain, with Baum not convincingly articulating the mechanism, timing, or confidence on how they'd meet guidance, which is a big tell for a credibility discount.
The company's FY26 guidance was base case, but there is also a bear case, with expectations now at $340-355M and 2027 back to epic growth, indicating a potential decline in the stock price.

Generated by AI

Topics

Of the messages about HROW that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	52.31%	4.4%
Earnings	—	—	0%	5.76%
Technical Analysis	—	—	0%	2.46%
Macro	—	—	41.54%	43.78%
Analysts	—	—	6.15%	43.26%
Controversies	—	—	0%	0.34%

Earnings· Nov 10

Harrow Health, Inc. ($HROW) reported Q3 2025 revenue of $71.6 million, a 45% increase year-over-year, but missed consensus estimates.
The company's adjusted EBITDA was $22.7 million, and GAAP net income was $1.0 million, with a net income of $0.03 per share.
Harrow Health's earnings beat consensus estimates for adjusted EPS, but the revenue miss led to a 9% stock price drop.

Announcements· Sep 26

Harrow Health, Inc. ($HROW) has agreed to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company developing non-opioid sedation therapies for medical procedures.
The acquisition includes an initial cash payment of $4.3M, with contingent payments of up to $261M tied to milestones such as FDA approval and commercialization of Melt's sedation drug candidate.
Melt's sedation drug candidate, MELT-300, has the potential to become a blockbuster product, with annual revenue exceeding $1B, according to Harrow's CEO, Mark Baum.

Generated by AI

Community

Of the messages about HROW, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	87.5%	87.39%	57.54%
Newcomers	—	12.5%	12.61%	42.46%

Regulars· Sep 11

The regulars are focusing on the company's poor management of expectations, which has led to a loss of credibility and a negative impact on the stock price.
The IHEEZO product is seen as a key driver of growth, with a potential to become a game-changer in the ocular anesthesia market, and the company's recent clinical displacement study results are seen as a positive development.
The company's management is reaffirming its revenue goals for 2027, and is planning to introduce segment reporting across Ocular Surgery, Retina, and Ocular Surface, which is seen as a positive development for institutional analysts and investors.

Newcomers· Nov 11

The CEO's overpromising and missing revenue targets are major concerns, potentially leading to a decline in the company's stock price.
The company's profitability has seen significant growth, with adjusted EPS increasing by 37.5% and net income becoming profitable.
The stock price has been volatile, with a 16% drop after hours and a subsequent 8% gain, suggesting that market expectations and perceptions are in flux.

Generated by AI

Harrow

Social

Sep 11

Bullish· Aug 11

Bearish· May 12

Earnings· Nov 10

Announcements· Sep 26

Regulars· Sep 11

Newcomers· Nov 11

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

Earnings call transcript: Harrow Health misses Q2 2026 EPS as revenue rises

Harrow Health, Inc. Q2 2026 Earnings Call Summary

Harrow Health earnings missed by $0.35, revenue fell short of estimates

Harrow Health falls 4.5% on earnings miss despite revenue growth

Harrow Announces Second Quarter 2026 Financial Results

Also Discussed

Harrow Inc.

Company Information

Location

Analysts’ Top NA Picks: Harrow Health (HROW), Scribe Therapeutics Inc. (SCTX)

Earnings call transcript: Harrow Health misses Q2 2026 EPS as revenue rises

Harrow Health, Inc. Q2 2026 Earnings Call Summary

Harrow Health earnings missed by $0.35, revenue fell short of estimates

Harrow Health falls 4.5% on earnings miss despite revenue growth

Harrow Announces Second Quarter 2026 Financial Results

Also Discussed

Social

Sep 11

Bullish· Aug 11

Bearish· May 12

Earnings· Nov 10

Announcements· Sep 26

Regulars· Sep 11

Newcomers· Nov 11